Effects of serum irisin, neuregulin 4, and weight management on obese adolescent girls with polycystic ovary syndrome.

Shunshun Cao,Yangyang Hu

doi:10.1042/bsr20211658

Abstract

The study is aimed at investigating the association of serum irisin, neuregulin 4 (NRG4), and anti-müllerian hormone (AMH) with adolescent obesity with polycystic ovary syndrome (PCOS) and the efficacy of weight management interventions. Serum levels of irisin, NRG4, AMH, sex steroid hormone, body mass index (BMI), serum insulin, and C-peptide were measured in 52 obese adolescent girls with PCOS (PCOS group) and 43 obese adolescent girls without PCOS (non-PCOS group). The levels of AMH, NRG4, serum irisin, sex steroid hormones, BMI, serum insulin, and C-peptide were evaluated in obese PCOS girls before and after one year weight management. The levels of AMH, serum insulin, NRG4, and total testosterone of PCOS group were significantly higher than those of non-PCOS group. On the contrary, serum irisin and serum C-peptide in PCOS group were significantly lower than that in non-PCOS group. The levels of fat mass, percent body fat, total testosterone, AMH, NRG4, and serum insulin in the obese girls with PCOS showed significant decreases compared with before weight management intervention. On the contrary, after one year of body weight management intervention, serum irisin and serum C-peptide was significantly increased. Adolescent obesity complicated with PCOS is significantly associated with glucose and lipid metabolism and sex steroid hormone disorders, but the exact pathophysiological and clinical features are highly variable. Weight management intervention can significantly improve the clinical symptoms and hematological indicators, serum irisin and NRG4 can be used as two essential biomarkers for evaluating weight management.

Highlights

Irisin was first reported in a paper published in Nature in January 2012, which brought new hope to the field of obesity clinical treatment, as researchers discovered new hormones in another class of brown fat and trans fat types
Our study found that the age and Tanner stage of polycystic ovary syndrome (PCOS) group (PCOS group age: 14.15 +− 0.31 vs. non-PCOS group age: 14.20 +− 0.15), (PCOS group tanner stage:0 (0%)/3 (6%)/49 (94%) vs. non-PCOS group tanner stage: 0 (0%)/2 (5%)/41 (95%)) were similar to those of non-PCOS group, and there was no statistical difference (P>0.05)
We found that the total testosterone, serum insulin serum neuregulin 4 (NRG4), and serum C-peptide of obese girls with PCOS were significantly higher than those of obese girls without PCOS

Summary

Introduction

Irisin was first reported in a paper published in Nature in January 2012, which brought new hope to the field of obesity clinical treatment, as researchers discovered new hormones in another class of brown fat and trans fat types. Some scholars have reported [1] that irisin is associated with metabolic diseases, including obesity, type 2 diabetes mellitus (T2DM), PCOS. Most studies have shown that irisin is positively correlated with obesity index [2]. From the perspective of pathophysiology, irisin is still an attractive target for the treatment of metabolic diseases, a large number of studies are still needed. Irisin is elevated in type 2 diabetes and is associated with elevated levels of E-selectin; irisin may constitute a potential new therapeutic opportunity in the areas of obesity and diabetes [3]. NRG4, a protein molecule containing a region similar to epidermal growth factor, is expressed

Objectives

Methods

Results

Discussion

Conclusion